

## COVINIB 2/4

**For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.**

Abbreviated Prescribing information for COVINIB (Baricitinib Tablets 2 mg/4 mg tablets)

[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

### PHARMACOLOGICAL PROPERTIES:

#### Therapeutic Indication:

BARICITINIB in combination with Remdesivir, for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, Invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

#### Mechanism of action:

Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. In isolated enzyme assays, Baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC<sub>50</sub> values of 5.9, 5.7, 53 and > 400nM, respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.

### DOSAGE AND ADMINISTRATION:

4 mg PO once daily for a recommended duration of 14 days or until hospital discharge, whichever comes first when given in combination with Remdesivir. Dosage adjustments in patients with renal or hepatic impairment are recommended.

**CONTRAINDICATION:** Hypersensitivity to the active substance or to any of the excipients of Baricitinib Tablets. There are no known contraindications for Baricitinib.

### WARNINGS & PRECAUTIONS:

There are limited clinical data available for Baricitinib used on COVID patient. Serious and unexpected adverse events may occur that have not been previously reported with Baricitinib use.

#### Serious Infections

Serious infections have occurred in patients receiving BARICITINIB:

- Avoid the use of BARICITINIB with known active tuberculosis.
- Consider if the potential benefits outweigh the potential risks of BARICITINIB treatment in patients with active serious infections besides COVID-19.

#### Thrombosis

In hospitalized patients with COVID-19, prophylaxis for VTE is recommended unless contraindicated. If clinical features of deep vein thrombosis/pulmonary embolism occur, patients should be evaluated promptly and treated appropriately.

### **Abnormal Laboratory Values**

Evaluate at baseline and thereafter according to local patient management practice. Monitor closely when treating patients with abnormal baseline and post-baseline laboratory values.

### **Vaccinations**

Avoid use of live vaccines with BARICITINIB, until four weeks after stopping Baricitinib.

### **Hypersensitivity**

If a serious hypersensitivity occurs, discontinue BARICITINIB while evaluating the potential causes of the reaction.

### **DRUG INTERACTION:**

Strong OAT3 Inhibitors: BARICITINIB exposure is increased when BARICITINIB is co-administered with strong OAT3 inhibitors (such as probenecid). In patients taking strong OAT3 Inhibitors, such as probenecid, rifampicin and cimetidine reduce the recommended dose as follows: • If the recommended dose is 4 mg once daily, reduce dose to 2 mg once daily. • If the recommended dose is 2 mg once daily, reduce dose to 1 mg once daily. • If the recommended dose is 1 mg once daily, consider discontinuing probenecid.

Other JAK Inhibitors or biologic disease modifying anti-rheumatic drugs (DMARDs): Baricitinib has not been studied in combination with other JAK inhibitors or with biologic DMARDs (biologic treatments targeting cytokines, B-cells or T-cells).

### **ADVERSE REACTIONS:**

Serious venous thrombosis, including pulmonary embolism and serious infections have been observed in COVID-19 patients treated with BARICITINIB.

Frequency estimate: Very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1,000$ ), very rare ( $< 1/10,000$ ).

### **Infections and infestations:**

*Very common:* Upper respiratory tract infections

*Common:* Herpes zoster, Herpes simplex, Gastroenteritis, Urinary tract infections, Pneumonia

### **Blood and lymphatic system disorders:**

*Common:* Thrombocytosis ( $>600 \times 10^9$  cells/L)

*Uncommon:* Neutropaenia ( $<1 \times 10^9$  cells/L)

### **Metabolism and nutrition disorders:**

*Very common:* Hypercholesterolaemia

*Uncommon:* Hypertriglyceridaemia

### **Nervous system disorder:**

*Common:* Headache

### **Gastrointestinal disorders:**

*Common:* Nausea, Abdominal pain

*Uncommon:* Diverticulitis

### **Hepatobiliary disorders:**

*Common:* ALT increased ( $\geq 3$  x ULN)

*Uncommon:* AST increased ( $\geq 3$  x ULN)

**Skin and subcutaneous tissue disorders:**

*Common:* Rash, Acne

**Immune disorders:**

*Uncommon:* Swelling of the face, Urticaria

**Respiratory, thoracic, and mediastinal disorders:**

*Uncommon:* Pulmonary embolism

**Vascular disorders:**

*Uncommon:* Deep Vein Thrombosis

**Investigations:**

*Common:* Creatine phosphokinase increased ( $> 5$  x ULN)

*Uncommon:* Weight increased

**Marketed by:**



**IN/ COVINIB 2/4 mg/JUN-21/01/ABPI**

(Additional information is available on request)